Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
Cristoforo Comi(Vita-Salute San Raffaele University), Goeril Karlsson(Novartis (Switzerland)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Jack P. Antel(Montreal Neurological Institute and Hospital), Ludwig Kappos(Novartis (Switzerland)), H. Pöhlmann(Novartis (Switzerland)), Paul O’Connor, Shreeram Aradhye, Ernst W. Radue(University Hospital of Basel)
Cited by 158
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k